Invesco Ltd. - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is and the CUSIP is 40637HAD1. A total of 64 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Invesco Ltd. ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$50,628,000
+1.6%
60,000,0000.0%0.01%
+7.7%
Q2 2023$49,834,200
-2.0%
60,000,0000.0%0.01%
-7.1%
Q1 2023$50,850,600
-17.8%
60,000,000
-6.1%
0.01%
-22.2%
Q4 2022$61,863,507
+14.4%
63,900,0000.0%0.02%
+5.9%
Q3 2022$54,075,000
+23.8%
63,900,000
+29.1%
0.02%
+30.8%
Q2 2022$43,668,00049,500,0000.01%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Wellesley Asset Management 128,679,626$110,468,0065.49%
CAMDEN ASSET MANAGEMENT L P /CA 77,223,000$65,160,7672.42%
Penn Mutual Asset Management 1,555,000$1,312,1091.23%
ZAZOVE ASSOCIATES LLC 9,108,000$7,715,0000.80%
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP 50,000,000$42,190,0000.67%
LAFFER TENGLER INVESTMENTS, INC. 2,399$2,032,8230.60%
SHENKMAN CAPITAL MANAGEMENT INC 9,019,000$7,767,6720.58%
LINDEN ADVISORS LP 62,930,000$53,329,4250.55%
SSI INVESTMENT MANAGEMENT LLC 4,577,000$3,862,0740.32%
Sonora Investment Management Group, LLC 4,355,000$3,675,0600.31%
View complete list of HALOZYME THERAPEUTICS INC shareholders